SCHEMBL4097446

SCHEMBL4097446

O=C1c2ccccc2C(=O)N1c1ccc(CBr)cn1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
GRM1 Q13255 1/20 0.41
NR1H3 Q13133 2/20 0.40
HTT P42858 2/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
PPARA Q07869 2/20 0.37
MEN1 O00255 1/20 0.37
AGTR1 P30556 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PPARD Q03181 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30817656 1.00 NPC1 (0.44) NPC1ALDH1A1KDM4EGAACRHBP
SCHEMBL8606873 0.76 ALDH1A1 (0.45) NPC1ALDH1A1KDM4EGAANR1H3
SCHEMBL4090427 0.76 ALDH1A1 (0.46) ALDH1A1GRM1NR1H3MAPTPPARA
SCHEMBL12509556 0.75 KCNJ1 (0.46) NPC1ALDH1A1KDM4EGAACRHBP
SCHEMBL1922080 0.75 SMN1; SMN2 (0.56) NPC1ALDH1A1KDM4EGAAGRM1
SCHEMBL11584879 0.75 NPC1 (0.68) NPC1ALDH1A1KDM4EGAACRHBP
SCHEMBL30817655 0.74 NPC1 (0.44) NPC1ALDH1A1KDM4EGAAGRM1
SCHEMBL29176809 0.74 NPC1 (0.44) NPC1ALDH1A1KDM4EGAAGRM1
SCHEMBL4594655 0.74 NR1H3 (0.62) GAANR1H3PPARAMEN1KMT2A
Bromide SCHEMBL4875685 0.73 NR1H3 (0.60) GAANR1H3PPARAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117756782-A Preparation method of arbeli intermediate 5- [ (4-ethylpiperazine-1-yl) methyl ] pyridin-2-amine 江苏希迪制药有限公司 2024-03-26 CN disclosed
CN-117720459-A Preparation process of arbeli intermediate 5- [ (4-ethylpiperazine-1-yl) methyl ] pyridin-2-amine 江苏希迪制药有限公司 2024-03-19 CN disclosed
EP-1494671-B1 1-(4-PIPERIDINYL)BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS SCHERING CORP (US) 2011-10-19 EP disclosed
US-20090209554-A1 Thiazoliums as transketolase inhibitors ARRAY BIOPHARMA INC. (US) 2009-08-20 US disclosed
US-20090209554-A1 Thiazoliums as transketolase inhibitors ARRAY BIOPHARMA INC. (US) 2009-08-20 US disclosed
US-20090209554-A1 Thiazoliums as transketolase inhibitors ARRAY BIOPHARMA INC. (US) 2009-08-20 US disclosed
US-7220735-B2 Benzimidazolone histamine H3 antagonists SCHERING CORPORATION (US) 2007-05-22 US disclosed
US-7220735-B2 Benzimidazolone histamine H3 antagonists SCHERING CORPORATION (US) 2007-05-22 US disclosed
WO-2005095391-A1 THIAZOLIUMS AS TRANSKETOLASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209554-A1 Thiazoliums as transketolase inhibitors TKT, RRM2, TYMS NPC1 3755/4885ALDH1A1 766/4885KDM4E 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.